(NASDAQ: IMMX) IMMIX Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 42.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 100.7%.
IMMIX Biopharma's earnings in 2025 is -$20,896,913.On average, 4 Wall Street analysts forecast IMMX's earnings for 2025 to be -$19,193,516, with the lowest IMMX earnings forecast at -$19,943,415, and the highest IMMX earnings forecast at -$18,148,118.
In 2026, IMMX is forecast to generate -$21,468,303 in earnings, with the lowest earnings forecast at -$22,402,193 and the highest earnings forecast at -$20,197,099.